Effectiveness of Atomoxetine in the Treatment of Children With Encopresis

Türkoğlu, Serhat; Bi̇lgi̇ç, Ayhan; Uzun, Necati

doi:10.1097/jcp.0000000000000369

Cited by 4 publications

(2 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Furthermore, Golubchik and Weizman, in 2013, pointed out that the direct impact of Methylphenidate, Imipramine, and Atomoxetine on self-organizing skills, impulse control, and executive functioning may enable children to recognize and respond to internal cues for defecation, making them useful as part of the treatment process for FI [ 15 , 26 ]. The effects of Atomoxetine in the treatment of FI have been reported in the literature; however, one of the side effects of Atomoxetine, like Risperidone, is constipation, and thus, administration of Atomoxetine to patients with ADHD and comorbid FI can either improve or worsen FI [ 13 , 27 , 34 , 35 ]. These findings may shed a light on the effects of central nervous system medications on the gastrointestinal tract [ 36 ].…”

Section: Discussionmentioning

confidence: 99%

Efficacy of atypical antipsychotics in the treatment of fecal incontinence in children and adolescents: a randomized clinical trial

Zahed,

Fatahi,

Tabatabaee

et al. 2024

BMC Pediatr

View full text Add to dashboard Cite

Objectives Functional retentive overflow incontinence (retentive FI) is the most common cause of fecal soiling in children. Based on the clinical experiences, the treatment of retentive FI in patients with comorbid psychiatric disorders was accelerated when Risperidone was used as treatment for their psychiatric comorbidities; therefore, this study was conducted to evaluate the effect of risperidone in the treatment of retentive FI in children and adolescents. Methods In this double-blind, randomized, placebo-controlled trial, 140 patients aged 4–16 years eligible for the study were randomized into two groups, receiving either 0.25–0.5 mg of Risperidone syrup (n = 70) or maltodextrin syrup (placebo group, n = 70) every 12 h daily for 12 weeks. Sociodemographic data, including age, sex, weight, height, BMI, BMI z-score, and socioeconomic status, was recorded, and the number of nocturnal FI, diurnal FI, and painful defecations was measured. Results 136 participants (69 on Risperidone and 67 on placebo) were included in the study. Mean age of participants in the intervention and placebo groups were 7.2 ± 2.4 years and 8.0 ± 3.1 years, respectively. The mean number of nocturnal FI (Ptrend=0.39) and diurnal FI (Ptrend=0.48) in patients without psychiatric comorbidities, and the number of painful defecations for participants with and without psychiatric comorbidities (P = 0.49, P = 0.47, respectively) were not significantly different between the groups, but a significant effect was observed in diurnal FI after Risperidone treatment in patients with psychiatric comorbidities (P < 0.001). Conclusion Risperidone, when used along with other non-pharmacological interventions, may be helpful in treating FI in pediatric patients with psychiatric comorbidities.

show abstract

Section: Discussionmentioning

confidence: 99%

Efficacy of atypical antipsychotics in the treatment of fecal incontinence in children and adolescents: a randomized clinical trial

Zahed,

Fatahi,

Tabatabaee

et al. 2024

BMC Pediatr

View full text Add to dashboard Cite

show abstract

“…(12,17) The effects of Atomoxetine in the treatment of fecal incontinence have been reported in the literature, however, constipation is a side effect of Atomoxetine, such as risperidone, and administration of Atomoxetine to patients with ADHD and comorbid fecal incontinence can improve or worsen fecal incontinence. (10,18,23,24) These ndings may shed light on the effects of the central nervous system medications on the gastrointestinal tract, (25) and given the high comorbidity of psychiatric disorders with fecal incontinence, it may be necessary to develop a comprehensive treatment plan, considering the bene ts of psychopharmacotherapy.…”

Section: Discussionmentioning

confidence: 99%

Risperidone for the Treatment of Retentive Fecal Incontinence in Children and Adolescents: A Randomize Clinical Trial

Zahed

Fatahi

Tabatabaee

et al. 2022

Preprint

View full text Add to dashboard Cite

Background: Functional retentive overflow incontinence (Retentive FI) is the most common cause of fecal soiling in children. Based on the clinical experiences, patients with retentive FI and comorbid psychiatric disorders, were accelerated in their treatment of fecal incontinence when they were being treated with Risperidone for their psychiatric comorbidities, therefore this study was conducted to evaluate the effect of Risperidone in the treatment of Retentive FI in children and adolescents. Method: In this double-blind randomized clinical trial, 170 patients aged 4-16 years eligible for the study were randomly divided into two groups receiving Risperidone (n=70) and placebo (n=70). About half of these patients had newly diagnosed psychiatric disorders and were drug naïve, this was considered in their division. Participants received a daily dose of 0.25-0.5 mg every 12 hours of Risperidone syrup (intervention group) or maltodextrin (placebo group) for 12 weeks. Sociodemographic data including age, sex, weight, height, BMI and BMI z-score (equivalent BMI-for-age percentile), and socioeconomic status were recorded. nocturnal fecal incontinence, diurnal fecal incontinence and painful defecations information was collected from subjects. Results: 136 participants (69 on Risperidone and 67 on placebo) completed the intervention. Mean age of participant in the intervention and placebo groups were 7.2±2.4 years and 8.0±3.1 y, respectively. The mean number of nocturnal fecal incontinence (Ptrend=0.39), diurnal fecal incontinence (Ptrend=0.48) and painful defecations for participants with and without psychiatric comorbidities were not significantly different between the groups (P=0.49, P=0.47, respectively). While, a significant interaction was observed between time and psychiatric comorbidities (P <0.001) for diurnal fecal incontinence after treatment with Risperidone.Conclusion: Based on our findings in this study, Risperidone, used commonly for psychiatric disorders in children and adolescents, may be useful in the treatment of retentive fecal incontinence in the presence of psychiatric comorbidities, and along with other interventions.

show abstract

Atomoxetine Successfully Addresses Double-Sphincteric Incontinence in a Child With Attention-Deficit/Hyperactivity Disorder

Naguy

2016

J Clin Psychopharmacol

View full text Add to dashboard Cite

Effectiveness of Atomoxetine in the Treatment of Children With Encopresis

Cited by 4 publications

References 8 publications

Efficacy of atypical antipsychotics in the treatment of fecal incontinence in children and adolescents: a randomized clinical trial

Efficacy of atypical antipsychotics in the treatment of fecal incontinence in children and adolescents: a randomized clinical trial

Risperidone for the Treatment of Retentive Fecal Incontinence in Children and Adolescents: A Randomize Clinical Trial

Atomoxetine Successfully Addresses Double-Sphincteric Incontinence in a Child With Attention-Deficit/Hyperactivity Disorder

Contact Info

Product

Resources

About